Literature DB >> 3668661

Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab.

B A Khaw1, T Yasuda, H K Gold, R C Leinbach, J A Johns, M Kanke, M Barlai-Kovach, H W Strauss, E Haber.   

Abstract

Indium-111 monoclonal antimyosin Fab scintigraphy was used to detect myocardial necrosis in 52 of 54 patients (96.3%) with acute myocardial infarction. Infarcts were visualized when coronary arteries were persistently occluded (n = 10), became patent after thrombolysis (n = 33), or became patent after spontaneous reperfusion (n = 7). Posteroinferolateral visualizations were obtained in two patients with clinical and enzymatic evidence of infarction but normal electrocardiograms. Of the two patients in whom no infarcts were visualized, one had an anterior myocardial infarct. This patient underwent successful thrombolytic therapy, with attendant minimization of creatine kinase release. The other patient had a small, nonreperfused inferior myocardial infarct. Five patients with a history of remote infarction and acute necrosis showed antimyosin uptake only in regions concordant with the acute episodes of infarction, and radiolabeled antimyosin Fab localized in neither old infarcts nor normal, noninfarcted myocardium. Antimyosin Fab scintigraphy, thus, appears to be a highly specific means of delineating necrotic myocardium, at least in this limited and selected group of patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668661

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  40 in total

1.  Differentiation of myocardial ischemia and necrosis by technetium 99m glucaric acid kinetics.

Authors:  R S Beanlands; T D Ruddy; L Bielawski; H Johansen
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

2.  Myocardial uptake of antimyosin antibody compared with serum myosin light chain I levels in patients with myocardial infarction.

Authors:  M Suehiro; M Fukuchi; H Naruse; T Iwasaki
Journal:  Ann Nucl Med       Date:  1992-02       Impact factor: 2.668

Review 3.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 4.  Antibodies for molecular imaging in the cardiovascular system.

Authors:  Ban-An Khaw
Journal:  J Nucl Cardiol       Date:  2005 Sep-Oct       Impact factor: 5.952

5.  Doxorubicin cardiotoxicity detected by indium 111 myosin-specific imaging.

Authors:  J Lekakis; N Vassilopoulos; H Psichoyiou; P Athanassiadis; S Gerali; P Kostamis; S Moulopoulos
Journal:  Eur J Nucl Med       Date:  1991

6.  Indium-111 myosin-specific antibodies and technetium-99m pyrophosphate in the detection of acute cardiac rejection of transplanted hearts: studies in a heterotopic rat heart model.

Authors:  K Takeda; K Ueda; U Scheffel; H Ravert; N D LaFrance; W A Baumgartner; B A Reitz; A Herskowitz; H N Wagner
Journal:  Eur J Nucl Med       Date:  1991

Review 7.  Radionuclide noninvasive evaluation of heart failure beyond left ventricular function assessment.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  J Nucl Cardiol       Date:  2009-02-27       Impact factor: 5.952

Review 8.  Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?

Authors:  J F Chatal; P Peltier; M Bardiès; A Chétanneau; P Thedrez; A Faivre-Chauvet; J F Gestin
Journal:  Eur J Nucl Med       Date:  1992

9.  Technetium-99m antimyosin antibody (3-48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction.

Authors:  R Taillefer; L Boucher; R Lambert; J Grégoire; D C Phaneuf; H Sikorsa
Journal:  Eur J Nucl Med       Date:  1995-05

10.  New application of myocardial antimyosin scintigraphy: diagnosis of myocardial disease in polymyositis.

Authors:  D Le Guludec; F Lhote; P Weinmann; I Royer; B Jarrousse; N Caillat-Vigneron; L Guillevin; J L Moretti
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.